human
influenza
b
virus
caus
signific
morbid
mortal
particularli
infant
elderli
peopl
suffer
preexist
patholog
unit
state
center
diseas
control
prevent
estim
season
influenza
epidem
respons
annual
hospit
annual
averag
death
approxim
death
occur
among
adult
age
evad
immun
respons
circul
influenza
b
virus
continu
chang
antigen
explain
current
influenza
vaccin
requir
annual
updat
vaccin
provid
inadequ
protect
target
popul
particularli
elderli
besid
concern
wide
spread
highli
pathogen
avian
influenza
viru
may
acquir
human
transmiss
becom
potenti
disastr
pandem
viru
human
rate
avian
report
although
investig
rais
possibl
subclin
case
infect
human
may
remain
comparison
rate
influenza
viru
estim
shown
figur
influenza
viru
replic
cycl
contain
sever
step
amen
antivir
intervent
review
focus
viral
entri
pathway
given
acut
onset
influenza
viru
infect
inflamm
associ
particularli
attract
process
interfer
describ
current
insight
structur
function
viral
cellular
compon
involv
entri
process
antivir
strategi
explor
overview
describ
compound
given
tabl
antivir
approach
affect
stage
viral
life
cycl
reader
refer
recent
review
effect
antivir
drug
prevent
treat
influenza
infect
time
avail
today
two
class
viru
drug
exist
proton
channel
blocker
ie
adamantan
compound
amantadin
rimantadin
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
first
two
compound
limit
util
sinc
associ
neurolog
side
effect
activ
influenza
b
viru
vast
major
circul
strain
detail
descript
mode
action
resist
mechan
given
obvious
superior
class
viru
drug
nai
oseltamivir
zanamivir
activ
influenza
b
virus
structur
analogu
sialic
acid
bind
catalyt
pocket
viral
na
inhibit
function
releas
newli
produc
viru
host
critic
differ
na
bind
mode
oseltamivir
compar
zanamivir
explain
significantli
differ
resist
profil
due
larger
hydrophob
side
chain
oseltamivir
requir
rotat
noncatalyt
residu
within
na
creat
bind
space
contrast
smaller
size
zanamivir
enabl
direct
bind
compound
na
mutant
na
contain
tyr
substitut
posit
rotat
longer
occur
render
na
resist
oseltamivir
bind
season
virus
isol
globe
even
untreat
japanes
studi
nine
children
treat
oseltamivir
carri
fortun
virus
still
sensit
zanamivir
resist
scarc
hand
administr
rout
zanamivir
ie
powder
inhal
devic
explain
oseltamivir
given
oral
capsul
gener
prefer
clinic
set
inhal
zanamivir
priori
exclud
patient
suffer
sever
influenza
symptom
acut
respiratori
distress
patient
infect
highli
pathogen
avian
viru
sever
case
pandem
viru
address
issu
intraven
formul
zanamivir
besid
new
nai
develop
peramivir
administ
intraven
licens
japan
south
korea
unit
state
use
temporarili
allow
unfortun
widespread
mutant
show
intermedi
anoth
nai
laninamivir
approv
japan
current
phase
iii
trial
unit
promis
compound
requir
one
singl
intranas
administr
base
long
similar
na
bind
mode
favor
resist
profil
final
novel
nai
sialic
unrel
structur
develop
ration
design
still
earli
experiment
face
emerg
resist
nai
particular
oseltamivir
entir
novel
viru
drug
urgent
need
two
product
advanc
clinic
develop
nucleobas
analogu
favipiravir
receptor
destroy
protein
phase
iii
trial
unit
state
pend
activ
metabolit
recogn
influenza
viru
polymeras
caus
competit
inhibit
viral
rna
synthesi
andor
lethal
viral
broad
viru
activ
beyond
influenza
viru
presum
base
cell
cultur
data
high
barrier
viral
second
agent
current
phase
ii
trial
recombin
protein
sialidas
cleav
influenza
viru
receptor
airway
epithelia
detail
provid
section
within
influenza
viru
particl
rna
genom
divid
eight
viral
ribonucleoprotein
vrnp
segment
protect
capsid
shell
form
protein
surround
viral
envelop
two
viral
spike
protein
protrud
virion
hemagglutinin
ha
na
lead
role
viral
entri
releas
respect
ha
na
glycoprotein
main
antigen
host
immun
respons
rais
case
influenza
viru
ha
na
subtyp
known
present
aquat
bird
natur
reservoir
influenza
except
isol
recent
emerg
new
pandem
viru
explain
reassort
genom
segment
occasion
occur
upon
dual
infect
anim
speci
pig
carri
well
influenza
viru
influenza
viru
ha
fig
homotrimer
type
membran
glycoprotein
globular
head
domain
contain
receptor
bind
site
rb
wherea
ha
stem
structur
contain
fusion
peptid
respons
intraendosom
membran
influenza
cell
ha
first
synthes
precursor
protein
assembl
noncoval
link
cleav
two
polypeptid
contain
case
amino
acid
respect
remain
coval
attach
disulfid
cleavag
occur
singl
arginin
residu
perform
secret
serin
proteas
restrict
bronchiolar
epithelium
tryptas
clara
human
airway
proteas
highli
pathogen
avian
virus
contain
seri
basic
residu
cleavag
allow
recognit
intracellular
proteas
wide
distribut
avian
tissu
thu
explain
system
spread
high
inhibit
cellular
proteas
perform
cleavag
origin
antivir
strategi
peptidomimet
furin
inhibitor
proven
inhibit
replic
avian
influenza
viru
cell
cleavag
minor
rearrang
lead
insert
fusion
peptid
locat
neg
charg
caviti
thu
prime
ha
posttransl
modif
ha
compris
addit
acyl
chain
short
cytoplasm
sever
asparagin
residu
besid
mask
antigen
epitop
steric
hinder
antibodi
glycan
also
function
correct
fold
ha
endoplasm
modul
receptor
control
maintain
ha
metast
conform
requir
fusion
conserv
among
variou
influenza
locat
cleavag
ha
stem
influenza
ha
subtyp
classifi
two
phylogenet
group
fig
belong
clade
within
group
wherea
ha
belong
group
although
phylogenet
classif
primarili
base
ha
protein
sequenc
comparison
avail
ha
crystal
structur
indic
region
involv
membran
fusion
show
strike
similar
first
step
infect
cycl
ha
attach
via
rb
globular
head
sialyl
glycoprotein
glycolipid
host
epitheli
interact
highli
specif
sialylglycoconjug
play
essenti
part
speci
recognit
avian
versu
human
influenza
virus
includ
pandem
virus
subtyp
preferenti
bind
glycan
termin
residu
gal
wherea
avian
influenza
virus
prefer
influenza
b
virus
natur
detect
human
seal
show
bind
prefer
thu
import
underlin
speci
specif
interact
base
recognit
termin
sialic
acid
rather
linkag
vicin
galactos
sugar
beyond
correl
glycan
topolog
speci
specif
establish
cocryst
structur
well
glycan
array
regard
ha
residu
directli
involv
sialic
acid
bind
highli
conserv
across
differ
ha
subtyp
amino
acid
amino
acid
number
base
ha
sequenc
suffix
denot
locat
subunit
respect
lead
fix
orient
sialic
acid
rel
ha
although
sialic
acid
gener
consid
primari
attach
receptor
influenza
viru
abl
bind
enter
though
consider
less
effici
cell
surfac
sialic
acid
whether
attach
glycolipid
glycoprotein
remov
treatment
exogen
micromonospora
viridifacien
henc
propos
besid
sialic
acid
receptor
may
involv
influenza
viru
entri
work
either
independ
via
multistep
specif
amino
acid
residu
ha
govern
avian
versu
human
receptor
prefer
vari
among
differ
still
incomplet
understood
although
tropism
gener
link
residu
cross
speci
barrier
acquisit
human
receptor
bind
prefer
suffici
sinc
addit
amino
acid
chang
requir
particularli
influenza
viru
polymeras
recent
studi
avian
viru
pass
ferret
four
mutat
head
domain
ha
combin
hallmark
mutat
subunit
polymeras
complex
abl
lead
airborn
transmiss
viru
similar
studi
reassort
viru
carri
ha
avian
also
conclud
adapt
requir
combin
ha
mutat
switch
receptor
prefer
also
increas
stabil
ha
first
natur
type
bind
inhibitor
antibodi
rais
cours
influenza
viru
infect
neutral
antibodi
predominantli
direct
toward
surfac
globular
head
domain
pandem
patient
treat
human
blood
product
recov
influenza
eight
control
studi
report
recent
review
conclud
overal
rate
reduc
among
control
patient
among
treat
patient
treatment
effect
initi
earli
ie
less
day
pneumonia
becam
appar
histor
data
demonstr
passiv
immun
antibodi
consid
case
pandem
occur
obvious
safeti
consider
use
materi
need
address
eleg
method
isol
human
antibodi
report
simmon
et
prepar
neutral
monoclon
antibodi
memori
patient
recov
infect
two
monoclon
antibodi
effect
mous
influenza
model
administ
later
hr
attract
new
concept
develop
monoclon
antibodi
bind
conserv
rb
ha
henc
endow
heterosubtyp
ha
neutral
activ
first
human
monoclon
antibodi
direct
ha
encod
deriv
plasma
cell
person
immun
trival
influenza
vaccin
cocrystal
fab
fragment
ha
reveal
antibodi
act
sialic
acid
mimic
sinc
tip
complementar
determin
region
insert
rb
ha
fig
sinc
shown
neutral
isol
cover
period
year
interact
conserv
rb
resist
select
may
expect
rare
unless
associ
reduc
viral
howev
note
rb
ha
smaller
interact
site
therefor
form
addit
interact
rb
surround
residu
less
conserv
among
differ
broadli
act
monoclon
antibodi
bind
isol
librari
construct
bone
marrow
donat
season
influenza
infect
cocrystal
studi
demonstr
part
form
loop
insert
conserv
rb
ha
region
make
minim
contact
rb
surround
variabl
third
monoclon
antibodi
neutral
viru
region
shown
form
multipl
hydrophob
interact
within
rb
ha
rather
low
affin
bind
interact
compens
bival
igg
molecul
avid
effect
requir
broaden
neutral
activ
strain
regard
influenza
b
virus
human
monoclon
antibodi
reactiv
b
virus
yamagata
lineag
recogn
residu
near
human
monoclon
antibodi
shown
neutral
yamagata
victoria
lineag
b
virus
protect
mice
challeng
lethal
dose
influenza
although
therapeut
use
antibodi
may
appear
complic
parallel
seen
palivizumab
antibodi
alreadi
use
prophylaxi
anoth
respiratori
viru
respiratori
syncyti
viru
rsv
innov
strategi
improv
pharmacokinet
reduc
product
cost
therapeut
antibodi
consist
antibodi
fragment
also
refer
nanobodi
deriv
camelid
nanobodi
direct
globular
head
ha
shown
effect
mice
activ
monoval
nanobodi
increas
factor
use
bival
format
consist
two
paratop
contain
domain
connect
flexibl
anoth
type
immun
protein
capabl
catch
virus
collagen
lectin
refer
collectin
lung
surfact
protein
role
surfact
protein
innat
immun
respons
influenza
viru
explain
capac
caus
viru
particl
aggreg
therebi
prevent
viru
attach
host
besid
variou
immunolog
effect
account
abil
limit
lung
inflamm
respiratori
regard
potenti
antivir
use
design
modifi
form
porcin
lectin
higher
viru
activ
human
counterpart
aid
grow
insight
carbohydr
recognit
domain
crd
precis
interact
glycan
attach
near
rb
addit
sialoglycan
attach
crd
consid
import
sinc
may
caus
addit
interact
ha
rb
enhanc
antivir
similar
action
principl
bind
carbohydr
viral
ha
account
viru
activ
bovin
serum
lectin
likewis
lectin
isol
escherichia
coli
recogn
oligosaccharid
structur
divers
viral
glycoprotein
explain
broad
activ
unrel
virus
influenza
viru
shown
inhibit
influenza
viru
replic
cell
cultur
well
mous
ferret
infect
although
manifest
broad
b
viru
activ
viru
strain
strain
known
insensit
due
lack
particular
oligosaccharid
head
locat
number
glycan
attach
head
ha
quit
variabl
sinc
acquisit
epitop
shield
oligosaccharid
part
viral
immun
contrast
glycan
attach
ha
stem
structur
function
protein
refold
correspond
glycosyl
site
therefor
impli
antivir
use
lectin
compound
direct
toward
ha
head
glycan
might
lead
escap
mutant
devoid
specif
glycan
although
newli
expos
antigen
site
might
also
render
mutat
viru
suscept
immunolog
altern
approach
block
ha
rb
make
use
receptor
mimic
macromolecul
gangliosid
sialylparaglobosid
spg
proven
bind
ha
inhibit
cytopath
antivir
activ
correl
ha
bind
hydrophob
ceramid
moieti
spg
found
essenti
sinc
uncoupl
trisaccharid
constitut
termini
spg
respect
produc
effect
micel
format
gangliosid
aqueou
solut
like
caus
protrus
sialic
acid
part
toward
outsid
micel
result
high
sialic
acid
densiti
henc
multival
bind
interact
recent
report
hendrick
et
al
describ
liposom
bear
c
lstc
form
multival
interact
influenza
contrast
monoval
lstc
decoy
liposom
abl
competit
bind
influenza
viru
hemagglutin
inhibit
assay
suppress
influenza
viru
replic
cell
cultur
mous
model
pentadecapeptid
bind
obtain
random
peptid
librari
serial
repeat
affin
select
dock
simul
indic
peptid
act
sialomimet
show
inhibitori
activ
influenza
virus
cell
jeon
et
al
use
peptid
sequenc
deriv
globular
head
region
ha
screen
dna
librari
aptam
select
aptam
proven
block
rb
ha
inhibit
influenza
virus
vitro
ie
cell
cultur
vivo
ie
anim
studi
anoth
macromolecul
sulfat
sialyl
lipid
fig
show
antivir
activ
influenza
b
recent
found
inhibit
influenza
viru
bind
cell
although
strong
neg
charg
henc
direct
interact
sialic
acid
bind
residu
ha
rb
anticip
precis
mode
action
antivir
compound
remain
determin
broad
activ
divers
virus
cell
cultur
well
anim
model
present
relev
antivir
lead
compound
opposit
strategi
block
bind
influenza
viru
cell
receptor
develop
sialic
acid
bind
compound
gangliosid
use
select
potenti
inhibitor
random
peptid
two
pentadecapeptid
gwwykgrarpvsava
ravwrhsvatpshsv
pick
acyl
group
order
form
molecular
assembl
promot
multival
bind
provid
inhibit
influenza
viru
infect
cell
cultur
viru
activ
compar
agglutinin
known
interact
final
third
strategi
inhibit
viru
bind
destruct
sialyl
glycan
receptor
year
ago
observ
cell
less
suscept
influenza
viru
infect
enzymat
remov
sialic
acid
cell
new
viru
agent
recombin
fusion
protein
consist
sialidas
catalyt
domain
deriv
actinomyc
viscosu
domain
effici
remov
sialic
acid
display
broad
activ
influenza
b
virus
well
parainfluenza
sinc
act
host
cell
rather
viru
assum
reduc
potenti
gener
drug
resist
passag
presenc
influenza
viru
mutant
select
low
moder
resist
compound
ie
increas
antivir
valu
resist
virus
show
attenu
phenotyp
compar
viru
yet
unchang
virul
mice
passag
absenc
compound
virus
quickli
regain
sensit
sequenc
reveal
resist
mutant
contain
substitut
ha
near
rb
well
na
lead
alter
ha
na
concern
desialyl
airway
epithelium
might
unmask
certain
cryptic
receptor
increas
suscept
streptococcu
pneumonia
contradict
mous
experi
show
treatment
lead
increas
incid
secondari
requir
topic
deliveri
inhal
current
phase
ii
clinic
trial
daili
dose
mg
day
treatment
prophylaxi
bind
sialyl
glycan
cell
surfac
influenza
virion
intern
endocytosi
gener
virus
intern
endocytosi
cme
endocytosi
macropinocytosi
less
character
earli
electron
microscop
analysi
influenza
cell
show
presenc
virion
pit
vesicl
provid
direct
evid
influenza
viru
enter
cell
cme
howev
sinc
virion
also
found
smooth
pit
viru
abl
follow
altern
support
came
investig
domin
neg
form
cellular
endocyt
regul
express
use
pharmacolog
inhibitor
cme
inhibitor
chlorpromazin
agent
nystatin
genistein
inhibitor
caveola
addit
evid
influenza
viru
exploit
cme
rout
parallel
provid
imag
rout
appear
equal
effici
support
infect
viru
recent
influenza
viru
uptak
shown
characterist
influenza
viru
entri
complet
inhibit
cell
simultan
treat
dynasor
amilorid
deriv
eipa
inhibit
cme
macropinocytosi
respect
sialic
acid
attach
site
influenza
viru
possess
host
cell
signal
capac
henc
addit
postattach
factor
may
requir
effici
viral
sinc
viru
fail
enter
cell
mutant
cho
cell
line
total
defici
glycosyl
suggest
glycoprotein
may
requir
effici
endocytosi
besid
bind
influenza
viru
cell
found
induc
lipid
raft
rearrang
activ
signal
molecul
epiderm
growth
factor
receptor
egfr
receptor
tyrosin
kinas
also
observ
activ
egfr
kinas
involv
promot
initi
viru
uptak
viru
intern
consider
reduc
presenc
genistein
broad
inhibitor
receptor
tyrosin
thu
precis
mechan
endocyt
uptak
influenza
viru
still
fulli
understood
whether
insight
may
translat
relev
antivir
concept
unsur
influenza
viru
appear
exploit
endocyt
rout
signal
platform
intim
link
normal
cell
function
thu
readili
amen
select
antivir
intervent
instanc
pharmacolog
agent
use
demonstr
role
cme
macropinocytosi
affect
viral
uptak
subtox
concentr
one
potenti
approach
use
membran
fluiditi
modul
restrict
movement
membran
molecul
neutral
glycolipid
fattiviracin
isol
streptomycet
interfer
fusion
cell
also
report
viru
interfer
cell
membran
fluiditi
may
also
princip
mode
action
glycyrrhizin
fig
main
activ
constitu
licoric
root
glycyrrhizin
broad
antivir
activ
divers
envelop
virus
includ
influenza
viru
herp
simplex
viru
hsv
viru
vzv
vaccinia
viru
vesicular
stomat
viru
measl
viru
sar
viru
activ
alreadi
demonstr
recent
flow
cytometr
intern
assay
use
show
glycyrrhizin
inhibit
endocyt
uptak
influenza
glycyrrhizin
proven
decreas
fluiditi
cell
membran
effect
attribut
chemic
fig
besid
antivir
effect
glycyrrhizin
display
immunomodulatori
combin
pharmacolog
effect
may
advantag
treatment
viru
infect
strong
inflammatori
compon
sever
airway
inflamm
cytokin
storm
caus
avian
japan
glycyrrhizin
alreadi
clinic
use
sinc
mani
year
base
compound
consid
favor
safeti
seriou
side
anoth
antivir
agent
interf
membran
fusion
aryl
methyldien
rhodamin
deriv
compound
display
activ
wide
rang
unrel
envelop
virus
includ
influenza
viru
yellow
fever
viru
hepat
c
viru
hcv
vesicular
stomat
viru
vaccinia
experi
demonstr
act
upon
viru
entri
sinc
inhibit
achiev
compound
ad
infect
shown
intercal
viral
well
cellular
membran
potent
antivir
activ
low
cytotox
explain
capac
host
cell
activ
rapid
biogen
repair
disrupt
virion
envelop
irrevers
lipoglycopeptid
lipophil
deriv
glycopeptid
antibiot
wide
use
antibiot
vancomycin
lipoglycopeptid
endow
increas
antibacteri
activ
also
display
activ
divers
virus
hiv
herp
virus
regard
influenza
viru
recent
describ
relationship
seri
aglycoristocetin
deriv
contain
lead
compound
carri
phenylbenzyl
substitu
display
strong
consist
activ
influenza
b
virus
resist
observ
viru
passag
cell
cultur
compound
shown
caus
intracytoplasm
trap
influenza
viru
prior
nuclear
entri
presum
disturb
endocyt
uptak
viru
site
plasma
membran
would
relev
see
whether
kistamicin
b
two
glycopeptid
report
viru
activ
sever
year
display
similar
mode
action
somewhat
suggest
fact
antivir
activ
higher
kistamicin
b
contain
lipophil
substitu
analog
altern
strategi
would
interfer
endosom
acidif
upon
intern
entri
earli
endosom
influenza
virus
undergo
initi
acidif
step
ph
traffic
late
endosom
acidif
ph
provid
trigger
fusion
endosom
viral
acidif
endosom
accomplish
cellular
vacuolar
proton
atpas
potent
select
inhibit
macrolid
antibiot
bafilomycin
concanamycin
compound
block
influenza
viru
entri
ad
within
first
min
differ
type
inhibitor
natur
compound
diphyllin
produc
surprisingli
potent
select
inhibit
influenza
viru
replic
cell
likewis
lysosomotrop
weak
base
ammonium
chlorid
chloroquin
inhibit
influenza
viru
entri
elev
endosom
chloroquin
show
vitro
viru
activ
concentr
base
data
use
malaria
prophylaxi
reach
howev
efficaci
trial
conclud
chloroquin
unabl
prevent
influenza
viru
agre
failur
prevent
influenza
viru
infect
mous
ferret
possibl
chloroquin
dose
use
clinic
studi
may
low
dose
estim
produc
blood
concentr
rang
antivir
concentr
cell
cultur
select
avoid
seriou
side
thu
although
bafilomycin
chloroquin
repres
excel
tool
examin
precis
mechan
influenza
viru
entri
relev
influenza
therapi
limit
explain
next
part
adamantan
compound
amantadin
rimantadin
block
influenza
viru
entri
mainli
inhibit
proton
channel
higher
concentr
rais
endosom
ph
due
basic
charact
therebi
affect
fusion
low
henc
virus
select
vitro
contain
mutat
either
ha
protein
ha
substitut
render
ha
less
stabl
thu
increas
ph
fusion
occur
recent
observ
virus
strain
particularli
sensit
subtl
increas
endosom
ph
caus
newli
synthes
amantadin
analogu
bear
differ
scaffold
structur
torr
unpublish
data
low
ph
insid
endosom
activ
viral
proton
channel
embed
viral
membran
lead
transport
proton
ion
interior
endosom
entrap
viru
result
vrnp
becom
dissoci
matrix
protein
uncoat
event
viral
genom
influenza
viru
short
polypeptid
residu
assembl
homotetramer
integr
membran
channel
protein
consist
short
unstructur
ectodomain
residu
ii
transmembran
helix
residu
respons
tetramer
proton
transloc
iii
cytoplasm
amphipath
helix
residu
involv
viru
assembl
bud
iv
disord
tail
residu
interact
matrix
fig
activ
ion
channel
ph
caus
proton
third
residu
proton
imidazol
ring
involv
interact
indol
ring
two
residu
function
ph
sensor
gate
respect
critic
proton
channel
function
henc
invari
among
influenza
b
besid
form
valv
control
entranc
proton
indirectli
hydrogen
bond
indol
nitrogen
via
water
cluster
exit
channel
thu
act
gatekeep
opposit
end
comparison
nmr
crystal
structur
transmembran
domain
obtain
neutral
ph
intermedi
ph
acid
ph
ph
provid
detail
insight
low
chang
protein
neutral
ph
valv
open
wherea
trp
basket
form
residu
oppos
end
small
hydrophob
open
ph
reduc
valv
constrict
trp
basket
two
mechan
proton
transport
aqueou
pore
propos
wire
model
proton
conduct
via
continu
column
water
molecul
open
pore
achiev
electrostat
repuls
proton
residu
accord
model
play
passiv
contrast
shuttl
model
play
activ
role
proton
transport
proton
deproton
facilit
imidazol
ring
reorient
backbon
analog
protein
protein
influenza
b
viru
form
homotetramer
integr
membran
protein
characterist
proton
channel
activ
ph
profil
similar
function
homolog
due
structur
transmembran
region
abl
form
stabl
tetram
without
amphipath
helix
necessari
tetramer
except
hxxxw
motif
transmembran
domain
trp
act
key
residu
proton
channel
activ
gate
share
littl
sequenc
homolog
furthermor
proton
channel
activ
higher
higher
conduct
may
part
explain
two
extra
serin
residu
channel
pore
facilit
proton
discoveri
adamantan
deriv
amantadin
rimantadin
fig
inhibit
influenza
viru
replic
made
decad
fact
instrument
elucid
function
amantadin
rimantadin
inact
influenza
b
virus
cocrystal
amantadin
transmembran
domain
identifi
drug
bind
site
channel
lumen
surround
residu
mutat
virus
particular
bind
amantadin
appar
lead
occlus
channel
pore
may
also
affect
proton
critic
hand
solut
nmr
channel
complex
rimantadin
reveal
four
equival
bind
site
locat
side
channel
adjac
helic
near
gate
way
bind
rimantadin
could
stabil
close
state
final
nmr
spectroscopi
phospholipid
bilay
show
exist
two
amantadin
bind
site
site
lumen
occupi
singl
amantadin
molecul
site
protein
surfac
becom
occupi
higher
amantadin
presenc
bind
site
confirm
molecular
dynam
simul
indic
amantadin
bind
insid
lumen
importantli
identif
bind
site
amantadin
rimantadin
provid
explan
compound
lack
activ
influenza
b
virus
compar
pore
two
serin
residu
probabl
disabl
bind
hydrophob
adamantan
moieti
within
also
residu
make
bind
site
amantadin
uncorrel
counterpart
mani
year
amantadin
rimantadin
success
use
prophylaxi
therapi
influenza
viru
infect
though
amantadin
associ
neurolog
side
nowaday
clinic
util
limit
sinc
circul
strain
thirti
percent
treat
patient
shed
mutant
replic
equal
well
viru
amantadin
rimantadin
readili
transmit
contact
season
viru
isol
resist
mutat
mostli
locat
transmembran
region
protein
common
chang
attempt
made
develop
new
adamantan
deriv
abl
interfer
ion
channel
activ
virus
guid
novel
structur
insight
bind
interact
amantadin
wang
et
al
recent
develop
inhibitor
potent
activ
mutant
molecul
larger
size
amantadin
therefor
abl
fill
upper
pore
even
volum
increas
substitut
one
compound
fig
show
antivir
activ
wild
type
well
mutant
virus
valu
similar
amantadin
imidazol
deriv
pinanamin
synthes
zhao
et
al
show
moder
inhibit
mutant
sever
research
group
develop
polycycl
amin
compound
achiev
potent
inhibitor
two
fine
exampl
imin
compound
fig
spiro
compound
fig
report
potent
amantadin
although
compound
found
amantadin
evalu
mutant
viru
serv
novel
scaffold
design
superior
blocker
anoth
studi
explor
size
limit
polycycl
amin
deriv
potenti
surprisingli
fig
fig
polycycl
compound
abl
bind
analogu
show
increas
bind
affin
compar
amantadin
biochem
studi
mutant
protein
molecular
dock
indic
compar
amantadin
one
deriv
show
differ
bind
mode
bind
site
ie
inner
channel
pore
region
delin
amantadin
target
channel
weak
base
also
indirectli
inhibit
fusion
concentr
least
higher
thu
altern
approach
develop
compound
react
target
similar
concentr
case
viral
resist
would
requir
appear
amino
acid
chang
two
separ
viral
protein
may
expect
rare
event
replac
primari
amino
group
amantadin
basic
secondari
tertiari
amino
group
addit
side
group
adamantan
ring
system
result
compound
interf
ha
lower
concentr
concentr
affect
proton
channel
activ
increas
howev
passag
viru
presenc
compound
escap
rate
still
high
yield
mutant
amino
acid
substitut
ha
reason
high
escap
rate
may
resist
mutat
select
compound
locat
differ
site
ha
without
reduct
viral
fit
low
ph
insid
late
endosom
lead
extens
irrevers
conform
chang
viral
ha
result
fusion
viral
endosom
membran
fig
key
role
play
fusion
peptid
defin
residu
conserv
region
ha
contain
seri
hydrophob
neutral
ph
fusion
peptid
sequest
pocket
ioniz
residu
upon
acidif
ph
influenza
virus
fusion
peptid
extrud
toward
target
membran
compar
crystallograph
structur
ectodomain
portion
ha
obtain
either
neutral
acid
ph
follow
rearrang
note
occur
low
ph
globular
head
domain
contain
rb
detrimer
ii
central
coil
coil
extend
interhel
chain
short
herebi
releas
fusion
peptid
buri
posit
iii
middl
long
two
turn
undergo
transit
form
revers
turn
posit
fusion
peptid
viral
membran
anchor
actual
membran
fusion
proce
hemifus
fig
accord
model
extrud
fusion
peptid
insert
endosom
membran
time
anchor
viral
membran
reorient
therebi
draw
endosom
viral
membran
togeth
mix
outer
membran
leaflet
prefus
stalk
intermedi
hemifus
diaphragm
form
mix
inner
outer
membran
leaflet
result
format
fusion
pore
allow
releas
vrnp
first
approach
interfer
fusion
process
inhibit
conform
chang
ha
use
small
molecul
bind
stabil
neutral
ph
conform
one
first
influenza
viru
fusion
inhibitor
report
hydroquinon
tbhq
fig
specif
inhibit
sever
year
later
bind
site
tbhq
within
ha
stem
structur
identifi
crystal
complex
shown
lie
within
hydrophob
pocket
form
interfac
ha
besid
sever
hydrophob
interact
tbhq
hydrogen
bond
side
chain
carbonyl
main
chain
carbonyl
one
monom
main
chain
carbonyl
anoth
monom
herebi
stabil
nonfusogen
ha
conform
chang
ha
critic
role
play
adjac
locat
short
involv
relev
hydrophob
pocket
around
develop
fusion
inhibitor
activ
group
confirm
studi
novel
viru
agent
fig
although
tbhq
differ
chemic
structur
notic
clear
similar
ha
bind
mode
tbhq
predict
carboxamid
part
howev
aromat
imidazo
thiazol
ring
allow
format
sever
addit
hydrophob
interact
within
caviti
inact
two
compound
group
virus
explain
analysi
ha
crystal
structur
reveal
residu
group
form
extra
turn
result
blockag
bind
unfortun
antivir
activ
restrict
virus
sinc
viru
shown
insensit
despit
fact
belong
phylogenet
group
also
resist
emerg
within
three
passag
cell
convers
sever
fusion
inhibitor
target
group
report
literatur
stachyflin
see
fig
chemic
structur
inhibit
conform
chang
test
ha
unfortun
activ
attempt
overrid
subtyp
depend
synthes
novel
deriv
prove
also
initi
predict
ha
bind
pocket
use
silico
dock
fulli
correl
subsequ
data
obtain
cocrystal
compound
ha
photoaffin
whatev
viru
specif
small
molecul
fusion
inhibitor
found
readili
select
resist
least
cell
cultur
two
type
resist
mutat
identifi
first
amino
acid
substitut
within
bind
pocket
affect
inhibitor
bind
ha
altern
ha
stabil
effect
inhibitor
counteract
ha
mutat
elev
fusion
ph
mean
mutant
ha
acquir
fusogen
conform
less
acid
thu
develop
type
small
molecul
fusion
inhibitor
hinder
viru
activ
low
barrier
resist
select
may
howev
way
inhibit
membran
fusion
instead
prevent
ha
refold
diiodofluorescein
induc
irrevers
conform
chang
ha
prematur
rearrang
result
virion
also
lead
inhibit
fusion
furthermor
may
possibl
interfer
membran
fusion
follow
ha
refold
event
mode
action
propos
dextran
sulfat
sulfat
polysaccharid
fig
antivir
activ
agent
report
inhibit
influenza
viru
also
hiv
rsv
hsv
viru
activ
dextran
sulfat
appear
restrict
influenza
virus
correl
molecular
weight
level
molecular
weight
increas
anion
dextran
sulfat
assum
form
electrostat
interact
viral
ha
net
posit
charg
ph
consist
fluoresc
microscopi
studi
show
bind
dextran
sulfat
dextran
sulfat
effect
viru
bind
found
inhibit
low
fusion
process
use
fusion
assay
base
fluoresc
direct
inhibit
refold
ha
howev
order
activ
compound
need
present
fusion
process
low
combin
data
suggest
dextran
sulfat
bind
site
might
inaccess
complex
dextran
sulfat
may
interfer
step
subsequ
conform
rearrang
ha
instanc
caus
steric
hindranc
membran
mix
remain
investig
whether
polysulf
polysaccharid
viru
activ
compound
isol
similar
mode
action
dextran
sulfat
anoth
high
molecular
weight
molecul
retrocyclin
also
act
wide
rang
virus
includ
influenza
viru
hiv
retrocyclin
circular
octadecapeptid
belong
antimicrobi
peptid
innat
immun
detail
mechanist
studi
show
inhibitori
effect
influenza
viru
replic
base
prevent
membran
fusion
low
howev
retrocyclin
remain
effect
ad
convers
ha
fusogen
conform
hemifus
intermedi
state
outer
membran
leaflet
merg
inner
leaflet
still
separ
thu
retrocyclin
propos
prevent
subsequ
membran
rearrang
caus
immobil
surfac
similar
interfer
membran
fusion
process
probabl
account
broad
viru
activ
arbidol
small
molecul
fig
licens
russia
china
influenza
viru
prophylaxi
therapi
besid
influenza
b
virus
antivir
spectrum
encompass
rsv
parainfluenza
viru
rhinoviru
hepat
b
viru
well
toler
drug
influenza
virus
yet
isol
howev
virus
obtain
viru
passag
cell
cultur
shown
carri
mutat
subunit
associ
increas
fusion
arbidol
may
thu
act
stabil
prefusogen
ha
protein
similar
manner
tbhq
small
molecul
fusion
inhibitor
describ
unlik
latter
compound
arbidol
less
altern
mode
action
propos
biochem
studi
variou
model
membran
show
arbidol
membranotrop
properti
particularli
due
interact
neg
charg
membran
sinc
membran
interact
pronounc
acid
fusion
ph
arbidol
could
alter
membran
fluiditi
fusion
process
make
bilay
less
likewis
inhibitori
effect
arbidol
toward
hcv
entri
explain
capac
dualli
interact
cell
membran
phospholipid
aromat
residu
tryptophan
present
glycoprotein
hcv
complex
would
prevent
conform
chang
viral
glycoprotein
requir
membran
time
dual
interact
arbidol
membran
phospholipid
influenza
viru
ha
mere
specul
mode
action
would
reconcil
biochem
virolog
vitro
data
outlin
context
vivo
studi
arbidol
may
also
immunostimulatori
properti
induc
activ
phagocyt
macrophag
stimul
humor
immun
alreadi
explain
sever
report
fusion
inhibitor
suffer
viru
activ
rapid
emerg
resist
drawback
could
avoid
target
fusion
peptid
highli
conserv
among
contain
residu
monoclon
antibodi
direct
first
residu
select
mice
immun
vitro
mab
antibodi
inhibit
syncytium
format
cell
indic
inhibit
fusion
process
administ
mice
mab
provid
protect
prophylact
though
highli
relev
yet
investig
recent
strategi
high
clinic
relev
come
discoveri
broad
neutral
antibodi
direct
rel
conserv
pocket
ha
stem
alreadi
first
antibodi
react
differ
ha
subtyp
mous
monoclon
antibodi
design
shown
neutral
belong
group
identif
resist
mutat
virus
obtain
viru
passag
presenc
antibodi
allow
locat
bind
site
middl
ha
stem
proven
inhibit
fusion
polykaryon
assay
influenza
shown
effect
first
human
antibodi
identifi
specif
either
group
group
obtain
systemat
screen
wide
array
individu
construct
combinatori
librari
antibodi
show
broad
neutral
activ
group
partial
overlap
bind
pocket
within
ha
crystal
complex
ha
reveal
conserv
hydrophob
tip
region
insert
hydrophob
pocket
adjac
short
ha
stem
therebi
allow
interact
antibodi
fusion
anoth
monoclon
antibodi
encod
interact
belong
group
cocrystal
ha
identifi
bind
pocket
lower
ha
stalk
thu
closer
proxim
viral
membran
compar
stabil
ha
prefusogen
conform
corrobor
find
antibodi
prevent
exposur
site
ha
viru
incub
low
broad
coverag
influenza
virus
could
achiev
combin
group
group
specif
antibodi
signific
progress
made
corti
et
al
success
isol
neutral
antibodi
recogn
group
group
interrog
larg
number
donor
plasma
cocrystal
antibodi
ha
protein
reveal
interact
conserv
epitop
f
fusion
henc
bind
optim
antibodi
assum
increas
stabil
f
subdomain
thu
prevent
conform
chang
ha
requir
membran
fusion
mode
action
accord
inhibitori
effect
syncytium
format
cell
altern
prevent
cleavag
least
virus
requir
extracellular
cleavag
ha
subunit
implic
activ
passiv
immun
shown
confer
prophylact
therapeut
protect
influenza
mice
recent
dreyfu
et
al
isol
human
monoclon
antibodi
neutral
influenza
b
recogn
epitop
ha
stem
nearli
ident
group
antibodi
howev
subtl
conform
differ
explain
antibodi
much
broader
reactiv
anoth
ha
antibodi
show
antivir
activ
group
virus
test
ie
virus
well
isol
viru
belong
group
howev
strain
isol
virus
inhibit
order
local
bind
epitop
ha
stem
author
select
escap
mutant
repeat
passag
viru
presenc
antibodi
similar
attempt
gener
escap
mutant
broad
neutral
antibodi
suggest
virus
mutat
correspond
ha
stem
region
readili
emerg
cell
cultur
instanc
antibodi
ten
viru
passag
studi
escap
mutant
observ
seem
indic
conserv
ha
stem
epitop
target
broad
act
antibodi
less
prone
mutat
due
fit
constraint
hypothesi
howev
still
remain
verifi
mutat
analysi
clear
discoveri
broad
neutral
stem
antibodi
offer
entir
new
perspect
passiv
activ
immun
influenza
virus
also
peptid
direct
conserv
epitop
ha
stem
region
develop
peptid
interact
epitop
recogn
sever
group
ie
concept
therapeut
peptid
use
inhibit
viru
fusion
valid
hiv
field
clinic
use
enfuvirtid
amino
acid
peptid
bind
hiv
disrupt
vrnp
matrix
protein
fusion
pore
format
vrnp
releas
cytoplasm
transport
vrnp
releas
partial
understood
intact
virion
protein
form
capsid
shell
locat
underneath
envelop
tightli
associ
current
insight
protein
structur
crucial
role
organ
virion
structur
recent
insid
endosom
acidif
virion
interior
lead
vrnp
uncoat
possibl
induc
conform
chang
recent
studi
indic
oligomer
state
oligom
intact
dissoci
stabl
dimer
acid
disappear
visibl
layer
virion
expos
ph
imag
cryoelectron
transport
fusion
pore
vrnp
appear
associ
residu
protein
insid
cytoplasm
dissoci
vrnp
final
allow
nuclear
second
dissoci
process
may
depend
cytosol
modif
phosphoryl
zinc
peptid
deriv
zinc
finger
domain
report
display
broad
potent
viru
activ
cell
cultur
ad
within
hr
infect
classifi
peptid
entri
far
know
attempt
report
explor
antivir
target
develop
potent
inhibitor
might
challeng
due
abund
presenc
protein
virion
last
free
vrnp
import
nucleu
via
nuclear
pore
vrnp
contain
one
eight
vrna
genom
segment
associ
singl
copi
viral
polymeras
heterotrim
pa
multipl
copi
nucleoprotein
np
although
four
viral
protein
contain
least
one
nuclear
local
signal
nl
vrnp
nuclear
import
appear
primarili
depend
nl
due
nl
vrnp
recogn
cargo
cellular
protein
format
ternari
complex
transport
specif
np
differ
isoform
differ
avian
human
virus
implic
role
influenza
viru
viral
np
structur
regulatori
function
influenza
viru
replic
besid
main
structur
compon
vrnp
np
crucial
role
consecut
replic
stage
regul
vrnp
nuclear
import
viral
rna
transcript
nuclear
export
via
interact
np
conserv
protein
sequenc
np
add
attract
antivir
target
sinc
implic
np
inhibitor
could
broadli
activ
across
differ
viru
illustr
small
molecul
ingavirin
inhibit
influenza
b
virus
vitro
ingavirin
report
inhibit
np
oligomer
subsequ
nuclear
import
newli
synthes
mechan
action
distinct
np
aggreg
agent
nucleozin
structur
analogu
compound
independ
identifi
sever
fig
np
bind
agent
display
viru
activ
influenza
virus
test
includ
first
report
nucleozin
proven
fluoresc
microscopi
caus
np
aggreg
trap
vrnp
nucleozin
also
activ
cellular
vrnp
reconstitut
assay
directli
measur
transcript
activ
indic
nucleozin
interfer
nuclear
entri
also
replic
process
np
involv
np
aggreg
activ
nucleozin
confirm
experi
np
cocrystal
relat
compound
format
higher
order
np
oligom
observ
two
np
trimer
link
six
molecul
compound
interact
two
antiparallel
bind
nitrophenyl
moieti
compound
interact
one
bind
pocket
close
np
residu
np
one
trimer
isoxazol
heterocycl
bind
bind
pocket
around
residu
np
trimer
vice
fig
data
nice
agre
resist
mutat
identifi
np
ie
viru
passag
presenc
np
bind
nucleozin
show
rather
modest
vivo
activ
protect
howev
full
protect
mice
obtain
compound
deriv
compound
improv
solubl
metabol
although
avail
antivir
strategi
direct
toward
viral
protein
possibl
block
cellular
compon
critic
role
viru
replic
receiv
increas
antivir
target
host
cell
factor
assum
reduc
select
ie
window
cytotox
antivir
efficaci
hand
resist
barrier
could
theori
higher
compar
direct
antivir
viru
high
mutat
rate
influenza
viru
appear
consider
two
studi
use
rna
interfer
screen
identifi
sever
host
cell
factor
necessari
influenza
viru
analys
base
pseudotyp
particl
entri
assay
allow
select
cellular
factor
regul
low
entri
among
protein
involv
kinas
c
pkc
signal
pathway
copi
compon
involv
endosom
traffick
vacuolar
atpas
fibroblast
growth
factor
son
dna
bind
protein
import
influenza
viru
traffick
late
endosom
intrigu
data
creat
new
opportun
design
antivir
concept
toward
host
cell
studi
compound
sirolimu
podophyllotoxin
inhibitor
host
cell
factor
found
inhibit
viru
replic
quit
remark
bisindolylmaleimid
compound
specif
inhibit
pkc
isoenzym
similar
potenc
block
site
catalyt
domain
bisindolylmaleimid
shown
interfer
influenza
b
viru
replic
earli
infect
probabl
affect
endocytosi
vesicl
isoform
proven
critic
influenza
viru
entri
sinc
accumul
viru
late
endosom
observ
cell
express
form
downstream
effector
aktprotein
kinas
b
signal
mediat
induc
influenza
viru
role
viru
replic
seem
upon
viru
attach
cell
activ
short
transient
manner
promot
step
viru
entri
preced
earli
late
endosom
later
stage
infect
influenza
viru
nonstructur
protein
induc
second
phase
sustain
activ
prevent
prematur
apoptosi
viral
propag
influenza
b
viru
protein
appar
lack
contrast
accumul
vrna
lead
activ
cell
infect
influenza
b
virus
final
signal
also
essenti
effici
activ
type
interferon
ifn
antivir
effect
ifn
mediat
interferon
induc
transmembran
ifitm
protein
result
inhibit
viral
genom
releas
notwithstand
complex
function
shown
inhibit
result
decreas
influenza
viru
make
pathway
potenti
antivir
target
past
year
signific
advanc
made
unravel
structur
influenza
viru
protein
involv
viru
entri
initi
attach
sialyl
receptor
nuclear
entri
avail
crystal
structur
ha
np
enabl
ration
design
directli
act
antivir
inhibitor
activ
virus
alreadi
report
old
paradigm
ha
appear
variabl
valid
antivir
target
challeng
macromolecul
inhibitor
lectin
antibodi
interact
conserv
site
ha
rb
stem
region
wherea
small
molecul
inhibit
conform
chang
ha
restrict
subtyp
depend
case
compound
arbidol
interfer
membran
fusion
event
recent
discov
np
aggreg
agent
nucleozin
repres
entir
novel
class
agent
clinic
relev
complementari
structur
studi
much
attent
current
given
complex
cell
biolog
influenza
viru
entri
pathway
particular
interest
host
cell
factor
involv
divers
compound
interf
cellular
factor
report
set
stage
new
type
indirectli
act
antivir
higher
barrier
resist
select
time
increas
resist
oseltamivir
agent
favor
resist
profil
inde
urgent
requir
